FMP

FMP

Enter

PCVX - Vaxcyte, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/PCVX.png

Vaxcyte, Inc.

PCVX

NASDAQ

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

74.37 USD

1.35 (1.82%)

PCVX Financial Statements

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Total Revenue

0

0

0

0

Cost of Revenue

0

4.5M

3.48M

3.09M

Gross Profit

0

-4.5M

-3.48M

-3.09M

Operating Expenses

162.17M

139.92M

149.5M

114.35M

Research and Development

133.61M

116.94M

131.51M

94.59M

Selling, General & Administrative Expenses

28.55M

22.99M

18M

19.89M

Selling & Marketing Expenses

0

0

-3.48M

0

General & Administrative Expenses

28.55M

22.99M

21.47M

19.89M

Other Expenses

0

0

-394k

0

Operating Income

-162.17M

-139.92M

-152.98M

-114.47M

Total Other Income/Expenses Net

25.09M

36.8M

24.28M

19.45M

Income Before Tax

-137.08M

-103.12M

-128.7M

-95.02M

Income Tax

0

0

0

-19.33M

Net Income

-137.08M

-103.12M

-128.7M

-95.02M

Basic EPS

-1.12

-0.83

-1.1

-0.85

EPS Diluted

-1.12

-0.83

-1.1

-0.85

Basic Average Shares

122.85M

123.69M

117.26M

111.69M

Diluted Average Shares

122.85M

123.69M

117.26M

111.69M

EBITDA

-52.58M

-139.92M

-152.98M

-113.47M

Retained Earning Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Retained Earnings (Previous Year)

-1.25B

-1.15B

-1.02B

-924.39M

Net Income

-137.08M

-103.12M

-128.7M

-95.02M

Stock Repurchases

0

5.53M

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-1.39B

-1.25B

-1.15B

-1.02B

Other Distributions

-137.08M

-97.6M

-128.7M

-95.02M

PPE Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Gross PPE

332.62M

249.93M

152.75M

157.31M

Annual Depreciation

4.79M

0

3.48M

3.09M

Capital Expenditure

-30.03M

-38.08M

-45.37M

-12.07M

Net PPE

357.87M

288.01M

194.65M

166.3M

Intangible and Goodwill Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep